ALEMBIC LTD
Add to watch list to get report alerts
BSE Code:
506235
NSE Code:
ALEMBICLTD
Business Profile
Business Profile
Alembic an integral part of the Alembic group of companies was incorporated on July 30, 1907 as Alembic Chemical Works Company. It was renamed Alembic with effect from May 31, 1999. ALEMBICLTD is a leading pharmaceutical company in India. The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Chirayu R. Amin is the chairman of the company.
Alembic is the market leader in the macrolides segment of anti-infective drugs in India. Zero (sugar free), Glycodin (cough syrup) and Althrocin (erythromycin estolate) are some of the leading brands of the company. It also has products in the anti-infective, pain management, nutraceuticals, gastrointestinal, cardiovascular, anti-diabetic, gynaecological, critical care, and anti-histamine areas. Alembic?s veterinary segment products include Glycodin, Nimegesic, Azithral, Roxid, Althrocin S and Aldinir. Alembic entered into a licensing agreement for its novel drug delivery platform for Keppra- XR with UCB. It acquired Dabur Pharma`s domestic non-oncology business and will market the 24 brands it acquired from Dabur.
ALEMBICLTD `s manufacturing facilities are in Vadodara and Panelav in Gujarat and Baddi in Himachal Pradesh. The plant in Vadodara has the largest fermentation capacity in India. The Panelav facility houses both API (USFDA approved) and formulation manufacturing plants. The company has a state-of-the-art research centre in Vadodara. Alembic has a distribution network that spans 29 states in India and 75 countries globally. Alembic`s product Ceftiaxone is ranked No 1 in terms of unit sales in Russia.
The company`s registered office is located at Gujarat, India.
Financials
The company announced a substantial drop in standalone net profit for the quarter ended December 2008. During the quarter, the profit of the company declined 95.05% to Rs 20.80 million from Rs 420.20 million in the same quarter last year. Net sales for the quarter rose 8.87% to Rs 2,837.30 million, while total income for the quarter rose 6.04% to Rs 2,839.70 million, when compared with the prior year period. It posted earnings of Rs 0.15 a share during the quarter, registering 95.07% decline over prior year period.
Recent Developments
24-MAR-09
The compan has received an approval from United States Food and Drug Administration (USFDA) for a new drug, Fluoxetine in capsules form in the strengths of 10 mg, 20 mg and 40 mg respectively.
24-FEB-09
The company has received an approval for a new drug, Meprobamate Tablet from USFDA (United States Food and Drug Administration). The said generic drug, Meprobamate Tablet will be available in the strengths of 200 mg and 400 mg.
23-FEB-09
The company announced that it had received an approval for a new drug, Meprobamate Tablet from USFDA (United States Food and Drug Administration).
15-JAN-09
The company announced that it had received an approval for a new drug, Lithium Carbonate from USFDA (United States Food and Drug Administration).